Furthermore, leveraging high-resolution spatial omics technologies (e.g., spatial transcriptomics, spatial proteomics) will be crucial for mapping the spatiotemporal dynamics of the PSAP-GPR37/GPR37L1 axis across different stages of PD pathology and brain regions (e.g., substantia nigra, striatum), and for understanding its overall impact on the neuro-glial network. This evidence concerns the gene GPR37L1 and Parkinson disease.